Recent News

• 05.15.2026 - Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
• 04.22.2026 - Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
• 03.18.2026 - Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
• 02.17.2026 - Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
• 02.09.2026 - Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
• 01.02.2026 - Nutriband CEO Publishes Letter to Shareholders
• 12.29.2025 - Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
• 12.25.2025 - Nutriband Inc. Shares Interview with Chairman Serguei Melnik from NobleCon21
• 12.24.2025 - Nutriband Inc. Announces 2026 Annual Shareholders Meeting
• 12.22.2025 - Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Recent Filings

• 04.29.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.07.2026 - 8-K Current report
• 04.07.2026 - EX-99.1 EX-99.1
• 02.13.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.13.2026 - 8-K Current report
• 02.03.2026 - 8-K Current report
• 12.30.2025 - 8-K Current report
• 12.30.2025 - EX-99.1 EX-99.1
• 12.19.2025 - DEF 14A Other definitive proxy statements